Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Pliant Therapeutics, Inc.

< Previous 1 2 Next >
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Provides Update on BEACON-IPF
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics to Participate in the Stifel Healthcare Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.